Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | BRD4 | O60885 | 16/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956246 | 0.86 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL4676762 | 0.86 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL6964377 | 0.86 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL6959330 | 0.85 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL6960515 | 0.85 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL5745579 | 0.84 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL6965703 | 0.84 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL6964617 | 0.84 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL6964963 | 0.84 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 | |
| SCHEMBL6966336 | 0.83 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19BRD4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495024-B1 | DIPYRIDODIAZEPINONES AS REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-7105510-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-09-12 | — | — | US | disclosed |
| EP-1554276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-06-28 | — | — | EP | disclosed |
| EP-1655300-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-05-10 | — | — | EP | disclosed |
| EP-1294720-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-04-05 | — | — | EP | disclosed |
| EP-1554276-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2005-07-20 | — | — | EP | disclosed |
| EP-1495024-A1 | DIPYRIDODIAZEPINONES AS REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004085437-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-10-07 | — | — | WO | disclosed |
| US-20040106791-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-06-03 | — | — | US | disclosed |
| US-6706706-B2 | FOR PREVENTING PERINATAL TRANSMISSION OF HIV-1 FROM MOTHER TO BABY AND TREATING HIV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-03-16 | — | — | US | disclosed |
| US-20030195197-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-10-16 | — | — | US | disclosed |
| WO-2003080612-A1 | DIPYRIDODIAZEPINONES AS REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | WO | disclosed |
| US-6420359-B1 | 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-07-16 | — | — | US | disclosed |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195197-A1 | Non-nucleoside reverse transcriptase inhibitors | RCOR1, POLR2H, CCR4 | CYP3A4 74/4885CYP2C9 821/4885CYP2C19 721/4885 |
| US-20040106791-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, SUB1 | CYP3A4 274/4885CYP2C9 742/4885CYP2C19 1064/4885 |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | REV1, POLR2H, POLR2E | CYP3A4 560/4885CYP2C9 1933/4885CYP2C19 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.